Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Predict S.P.A. Class B ( (IT:PRE) ) has provided an update.
Predict S.p.A. has secured a contract worth Euro 99,300 under the ‘THE – Tuscany Health Ecosystem’ tender, announced by the Giovanni Paolo II Oncology Institute in Bari. This contract involves providing breath sample analysis services using the Mistral Sampler device, as part of the E.C.C.O. project aimed at developing non-invasive diagnostic methods for colorectal cancer prevention. This achievement highlights Predict’s leadership in breath analysis and its commitment to advancing preventive medicine through innovative technologies.
The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.
More about Predict S.P.A. Class B
Predict S.p.A., founded in 2008 in Bari, is an innovative SME in the healthcare sector. It operates through four Strategic Business Units focusing on in vivo diagnostic imaging, breath analysis, and digital healthcare technologies. The company is known for its innovative solutions like Mistral for non-invasive oncological screening, Aphel for AI-driven hospital support, and Optip for remote medical consultations. Predict collaborates with leading Italian universities and research institutes.
Average Trading Volume: 33,000
Technical Sentiment Signal: Strong Buy
See more data about PRE stock on TipRanks’ Stock Analysis page.